Adocia SA
PAR:ADOC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Ujjivan Small Finance Bank Ltd
NSE:UJJIVANSFB
|
IN |
|
L
|
Life Healthcare Group Holdings Ltd
JSE:LHC
|
ZA |
|
I
|
Idun Industrier AB (publ)
STO:IDUN B
|
SE |
|
W
|
Wah Wo Holdings Group Ltd
HKEX:9938
|
HK |
|
Sunny Optical Technology Group Co Ltd
HKEX:2382
|
CN |
|
Eurobio Scientific SA
PAR:ALERS
|
FR |
|
Urban Logistics Reit PLC
LSE:SHED
|
UK |
|
Nippon Yakin Kogyo Co Ltd
TSE:5480
|
JP |
Adocia SA
Total Current Liabilities
Adocia SA
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Adocia SA
PAR:ADOC
|
Total Current Liabilities
€19.8m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
13%
|
CAGR 10-Years
1%
|
|
|
Valneva SE
PAR:VLA
|
Total Current Liabilities
€93.3m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
7%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Total Current Liabilities
€72.3m
|
CAGR 3-Years
22%
|
CAGR 5-Years
18%
|
CAGR 10-Years
24%
|
|
|
Inventiva SA
PAR:IVA
|
Total Current Liabilities
€58.5m
|
CAGR 3-Years
24%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Total Current Liabilities
$58m
|
CAGR 3-Years
25%
|
CAGR 5-Years
2%
|
CAGR 10-Years
14%
|
|
|
Abivax SA
PAR:ABVX
|
Total Current Liabilities
€94m
|
CAGR 3-Years
43%
|
CAGR 5-Years
24%
|
CAGR 10-Years
30%
|
|
Adocia SA
Glance View
Adocia SA is a clinical-stage biotechnology company, which engages in the development of medicines from already-approved therapeutic proteins and peptides. The company is headquartered in Lyon, Auvergne-Rhone-Alpes. The company went IPO on 2012-02-20. The firm specializes in the development of formulations of already-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary technological platform BioChaperone is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. The Company’s clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two formulations of insulin analog lispro (BioChaperone Lispro U100 and U200), a combination of basal insulin glargine and insulin lispro (BioChaperone Combo), and a combination of prandial insulin with amylin analog pramlintide: M1Pram. Its preclinical pipeline includes three products BioChaperone LisPram, BioChaperone Glargine GLP-1 and BioChaperone Glucagon GLP1.
See Also
What is Adocia SA's Total Current Liabilities?
Total Current Liabilities
19.8m
EUR
Based on the financial report for Jun 30, 2025, Adocia SA's Total Current Liabilities amounts to 19.8m EUR.
What is Adocia SA's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
1%
Over the last year, the Total Current Liabilities growth was -3%. The average annual Total Current Liabilities growth rates for Adocia SA have been -5% over the past three years , 13% over the past five years , and 1% over the past ten years .
